Granted Patent
B2
US 12,350,399 · App. 18/204,233 · Granted Jul 8, 2025
Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
Inventors:
Damien Kudela (Santa Barbara, CA); Galen D. Stucky (Santa Barbara, CA); Anna May-Masnou (Barcelona, ES); Gary Bernard Braun (San Diego, CA); James H. Morrissey (Champaign, IL); Stephanie A. Smith (Urbana, IL)
Assignees:
The Regents of the University of California; The Board of Trustees of the University of Illinois
A61L24/046A61K47/595A61K47/6923A61K47/6935A61L24/02A61L2300/404A61L2300/418A61L2400/04A61L2400/12Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.
Claims (14)
1. A method of treating a subject for a wound, the method comprising:
administering a hemostatic agent to the subject, wherein the hemostatic agent comprises:
a magnetic nanoparticle; and
a polyphosphate polymer attached to the magnetic nanoparticle; and
magnetically tracking the movement of the magnetic nanoparticle of the hemostatic agent to the wound.
2. The method of claim 1 , wherein the tracking comprises imaging the hemostatic composition.
3. The method of claim 2 , wherein the imaging comprises imaging the magnetic nanoparticle.
4. The method of claim 2 or 3 , wherein the hemostatic agent further comprises a dye precursor that is convertable to a fluorescent dye by a coagulation factor, wherein the tracking comprises measuring fluorescence by the fluorescent dye at the wound.
5. The method of claim 4 , wherein the coagulation factor is thrombin.
6. The method of claim 1 , wherein the magnetic nanoparticle comprises a silver core.
7. The method of claim 1 , wherein the magnetic nanoparticle comprises a silica shell.
8. The method of claim 1 , wherein the magnetic nanoparticle comprises a material selected from the group consisting of iron oxide, diatomaceous earth, an aluminosilicate, an oxide of a transition metal, and titanium dioxide.
9. The method of claim 1 , wherein the hemostatic agent further comprises a protecting agent attached to the magnetic nanoparticle.
10. The method of claim 9 , wherein the protecting agent comprises polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(lactic-co-glycolic acid) (PLGA), polypropylene glycol, or a combination thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2023
From: KUDELA, DAMIEN; STUCKY, GALEN D.; MAY-MASNOU, ANNA; BRAUN, GARY BERNARD
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064648/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2023
From: MORRISSEY, JAMES H.; SMITH, STEPHANIE A.
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 064648/0341 →
Continuity (6)
Provisional Application
61775354
· Mar 8, 2013
References Cited (116)
US 7682808B2
· Morrissey
· 2010
[cited by applicant]
US 7927629B2
· Simone et al.
· 2011
[cited by applicant]
US 8257740B1
· Sung et al.
· 2012
[cited by applicant]
US 8821861B2
· Smith et al.
· 2014
[cited by applicant]
US 9061014B2
· Seward et al.
· 2015
[cited by applicant]
US 9186417B2
· Kudela
· 2015
[cited by examiner]
US 9241958B2
· Smith et al.
· 2016
[cited by applicant]
US 20100209946A1
· Jing et al.
· 2010
[cited by applicant]
US 20100297246A1
· Weitzmann et al.
· 2010
[cited by applicant]
US 20120244602A1
· Okumura et al.
· 2012
[cited by applicant]
US 20120282320A1
· Scherr
· 2012
[cited by examiner]
US 20150283287A1
· Agarwal et al.
· 2015
[cited by applicant]
US 20200297854A1
· Ingber et al.
· 2020
[cited by applicant]
EP 3062830
· 2016
[cited by applicant]
WO WO2001072313A1
· 2001
[cited by applicant]
WO WO2012101218
· 2012
[cited by applicant]
WO WO2012101218A1
· 2012
[cited by applicant]
WO WO2013173235A1
· 2013
[cited by applicant]
Suzawa et al., “Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate” in Journal of Controlled Release 69 (2000) pp. 27-4…
[cited by examiner]
Ong et al., “Development of chitosan-based wound dressing with improved hemostatic and antimicrobial properties,” in Biomaterials, vol. 29, Issue 32, Nov. 2008, pp. 4323-4332, cited by applicant in 1449 filed Feb. 19, 2…
[cited by examiner]
Suzawa et al., (2000) “Synthesis and HPLC Analysis of Enzymatically Cleavable Linker Consisting of Poly(Ethylene Glycol) and Dipeptide for the Development of Immunoconjugate”, J. Controlled Release 69(1):27-41.
[cited by applicant]
Choi et al., (2011) “Polyphosphate is a Cofactor for the Activation of Factor XI by Thrombin”, Blood, 118:6963-6970.
[cited by applicant]
Choi et al., (2010) “Phosphoramidate End Labeling of Inorganic Polyphosphates: Facile Manipulation of Polyphosphate for Investigating and Modulating its Biological Activities”, Biochemistry 49(45): 9935-9941.
[cited by applicant]
Morrissey et al., (2012) “Polyphosphate: An Ancient Molecule that Links Platelets, Coagulation and Inflammation”, Blood 119:5972-5979.
[cited by applicant]
Müller et al., (2009) “Platelet Polyphosphates are Proinflammatory and Procoagulant Mediators in vivo”, Cell 139:1143-1156.
[cited by applicant]
Mutch et al., (2010) “Polyphosphate Binds with High Affinity to Exosite II of Thrombin”, J Thromb Haemost 8:548-555.
[cited by applicant]
Semeraro et al., (2011) “Extracellular Histones Promote Thrombin Generation through Platelet-Dependent Mechanisms: Involvement of Platelet TLR2 and TLR4”, Blood 118:1952-1961.
[cited by applicant]
Smith et al., (2008) “Polyphosphate as a General Procoagulant Agent”, J Thromb Haemost 6:1750-1756.
[cited by applicant]
Smith and Morrissey (2008) “Polyphosphate Enhances Fibrin Clot Structure”, Blood 112:2810-2816.
[cited by applicant]
Smith et al., (2012) “Inhibition of Polyphosphate as a Novel Strategy for Preventing Thrombosis and Inflammation”, Blood, 120:5103-5110.
[cited by applicant]
Smith et al., (2010) “Polyphosphate Exerts Differential Effects on Blood Clotting, Depending on Polymer Size”, Blood 116: 4353-4359.
[cited by applicant]
Smith et al., (2006) “Polyphosphate Modulates Blood Coagulation and Fibrinolysis”, Proc Natl Acad Sci USA 103:903-908.
[cited by applicant]
Tavano et al., (2010) “Procoagulant Properties of Bare and Highly PEGylated Vinyl-Modified Silica Nanoparticles”, Nanomedicine (Lond) 5(6):881-896.
[cited by applicant]
Yun and Morrissey (2009) “Polyphosphate and Omptins: Novel Bacterial Procoagulant Agents”, J. Cell Molec. Med. 13:4146-4153.
[cited by applicant]
Kastrup et al., (2007) “Characterization of the Threshold Response of Initiation of Blood Clotting to Stimulus Patch Size”, Biophysical Journal 93(8), 2969-2977.
[cited by applicant]
Lorenz et al., (1994) “Preparation and Use of Polyphosphate-Modified Zirconia for Purification of Nucleic Acids and Proteins”, Anal. Biochem. 216:118-126.
[cited by applicant]
Stöber and Fink (1968) “Controlled Growth of Monodisperse Silica Spheres in the Micron Size Range”, Journal of Colloid and Interface Science 26:62-69.
[cited by applicant]
Riewald et al., (2003) “Science review: Role of coagulation protease casades in sepsis,” in Critical Care , 7: 123-129.
[cited by applicant]
Santomauro et al., (2012) “Bomineralization of Zinc-Phosphate-Based Nano Needles by Living Microalgae”, Journal of Biomaterials and Nanobiotechnology, 3: 362-370.
[cited by applicant]
Smith et al.; (2010) “Polyphophate exerts differential effects on blood clotting, depending on polymer size,” Blood, 116(20): 4353-4359.
[cited by applicant]
Aatonen et al., (2012) Platelet-Derived Microvesicles: Multitalented Participants in Intercellular Communication, Semin Thromb Hemost, 102-113, 38(01).
[cited by applicant]
Alam et al. (2005) Hemorrhage control in the battlefield: Role of new hemostatic agents. Military Medicine 170(1):63-69.
[cited by applicant]
Alam, et al. (2004) Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in swine. Journal of Trauma-Injury Infection and Critical Care 56(5):974-983.
[cited by applicant]
Baker et al. (2007) Controlling bioprocesses with inorganic surfaces: Layered clay hemostatic agents. Chem. Mater. 19(18):4390-4392.
[cited by applicant]
Baker et al. (2008) Blood clot initiation by mesocellular foams: dependence on nanopore size and enzyme immobilization. Langmuir 24(24):14254-14260.
[cited by applicant]
Bowman et al. (2011) Toxicity of aluminum silicates used in hemostatic dressings toward human umbilical veins endothelial cells, hela cells, and raw267.4 mouse macrophages.
[cited by applicant]
Bull et al. (2009) Postoperative bypass bleeding: A bypass- associated dilutional (BAD) coagulopathy?
[cited by applicant]
Cauda et al. (2010) Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake.
[cited by applicant]
Cauda et al.(2010) Impact of different PEGylation patterns on the long-term bio- stability of colloidal mesoporous silica nanoparticles.
[cited by applicant]
Cosgriff et al. (1997) Predicting life-threatening coagulopathy in the massively transfused trauma patient: Hypothermia and acidoses revisited.
[cited by applicant]
Darlington et al. (2011) Coagulation changes to systemic acidosis and bicarbonate correction in swine. Journal of Trauma-Injury Infection and Critical Care 71(5):1271-1277.
[cited by applicant]
Donovan et al. (2014) Size-Controlled Synthesis of Granular Polyphosphate Nanoparticles at Physiologic Salt Concentrations for Blood Clotting.
[cited by applicant]
Driscoll (1995) The toxicology of crystalline silica studied in vitro. (Proceedings of the International Conference on the Crystalline Silica Health Effects: Current State of the Art), pp. 1118-1125.
[cited by applicant]
Finnie et al. (2009) Biodegradability of sol-gel silica microparticles for drug delivery.
[cited by applicant]
Gaharwar et al. (2014) Shear-Thinning Nanocomposite Hydrogels for the Treatment of Hemorrhage. ACS Nano, 8(10): 9833-9842.
[cited by applicant]
Geeraedts et al. (2009) Exsanguination in trauma: A review of diagnostics and treatment options.
[cited by applicant]
Gerlach et al. (2010) Preliminary Study of the Effects of Smectite Granules (WoundStat) on Vascular Repair and Wound Healing in a Swine Survival Model.
[cited by applicant]
Ghadiri et al. (2014) Antibiotic eluting clay mineral (Laponite((R))) for wound healing application: an in vitro study.
[cited by applicant]
Gordy et al. (2011) Military applications of novel hemostatic devices.
[cited by applicant]
Gwinn & Vallyathan (2006) Nanoparticles: Health effects—Pros and cons.
[cited by applicant]
Hafeli et al., (2009) “Cell uptake and in vitro toxicity of magnetic nanoparticles suitable for drug delivery,” Molecular Pharmaceutics, Articles, 2009, 12 pages.
[cited by applicant]
Kheirabadi (2011) Evaluation of topical hemostatic agents for combat wound treatment.
[cited by applicant]
Kheirabadi et al. (2009) Comparison of new hemostatic granules/powders with currently deployed hemostatic products in a lethal model of extremity arterial hemorrhage in swine.
[cited by applicant]
Kheirabadi et al. (2009) Determination of Efficacy of New Hemostatic Dressings in a Model of Extremity Arterial Hemorrhage in Swine.
[cited by applicant]
Kheirabadi et al. (2010) Clot-inducing minerals versus plasma protein dressing for topical treatment of external bleeding in the presence of coagulopathy.
[cited by applicant]
Kheirabadi et al. (2010) Safety evaluation of new hemostatic agents, smectite granules, and kaolin-coated gauze in a vascular injury wound model in swine.
[cited by applicant]
Kheirabadi et al. (2013) In vivo assessment of the Combat Ready Clamp to control junctional hemorrhage in swine.
[cited by applicant]
Kudela et al. (2015) Clotting activity of polyphosphate functionalized silica nanoparticles
[cited by applicant]
Lashof-Sullivan et al. (2013) Intravenous hemostats: Challenges in translation to patients.
[cited by applicant]
Lee & Whitesides (2010) Analysis of inorganic polyphosphates by capillary gel electrophoresis.
[cited by applicant]
Li et al. (2013) Cytotoxicity and potency of mesocellular foam-26 in comparison to layered clays used as hemostatic agents.
[cited by applicant]
Lin et al. (2012) Critical considerations in the biomedical use of mesoporous silica nanoparticles.
[cited by applicant]
Lorenz et al. (1997) Anti-HIV-1 activity of inorganic polyphosphates.
[cited by applicant]
Lu et al. (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
[cited by applicant]
Martini & Holcomb (2007) Acidosis and coagulopathy—The differential effects on fibrinogen synthesis and breakdown in pigs. Annals of Surgery 246(5):831-835.
[cited by applicant]
Martini (2009) Coagulopathy by hypothermia and acidosis: Mechanisms of thrombin generation and fibrinogen availability.
[cited by applicant]
Martini et al. (2006) Does bicarbonate correct coagulation function impaired by acidosis in swine?
[cited by applicant]
Martini et al.(2005) Independent contributions of hypothermia and acidosis to coagulopathy in swine.
[cited by applicant]
Mellaerts et al. (2008) Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica.
[cited by applicant]
Nigretto JM, Corretge E, & Jozefowicz M (1989) Contributions of negatively charged chemical groups to the surface-dependent activation of human-plasma by soluble dextran derivatives.
[cited by applicant]
Ong et al. (2008) Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties.
[cited by applicant]
Ostomei et al. (2007) Metal oxide surface charge mediated Hemostasis.
[cited by applicant]
Ostomei et al. (2006) Host-guest composites for induced hemostasis and therapeutic healing in traumatic injuries.
[cited by applicant]
Park et al. (2009) Biodegradable luminescent porous silicon nanoparticles for in vivo applications.
[cited by applicant]
Park, et al. (2009) Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.
[cited by applicant]
Phillips et al. (2014) Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.
[cited by applicant]
Pozza & Millner (2011) Celox (chitosan) for haemostasis in massive traumatic bleeding: experience in Afghanistan.
[cited by applicant]
Pusateri et al. (2004) Application of a granular mineral-based hemostatic agent (QuikClot) to reduce blood loss after grade V liver injury in swine.
[cited by applicant]
Ramaker et al. (2009) Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point of care testing with the thromboelastography analyser.
[cited by applicant]
Rao & Sharma (1997) Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential.
[cited by applicant]
Reddy et al., (2012) “Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications,” Chemical Reviews, 5818-5878, 112,11.
[cited by applicant]
Rosenholm et al., (2011) “Multifunctional Mesoporous Silica Nanoparticles for Combined Therapeutic, Diagnostic and Targeted Action in Cancer Treatment,” Current Drug Targets, 1166-1186, 12, 8.
[cited by applicant]
Santomauro et al. (2012) Biomineralization of Zinc-Phosphate-Based Nano Needles by Living Microalgae.
[cited by applicant]
Sena et al. (2013) A pilot study of the use of kaolin-impregnated gauze (Combat Gauze) for packing high-grade hepatic injuries in a hypothermic coagulopathic swine model.
[cited by applicant]
Singh et al. (2011) Bioresponsive mesoporous silica nanoparticles for triggered drug release.
[cited by applicant]
Slowing et al. (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.
[cited by applicant]
Tarn et al. (2013) Mesoporous silica nanoparticle nanocarriers: Biofunctionality and biocompatibility.
[cited by applicant]
Thompson & Butterworth (1992) The nature of laponite and its aqueous dispersions.
[cited by applicant]
Trewyn et al. (2007) Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems.
[cited by applicant]
Vogler & Siedlecki (2009) Contact activation of blood-plasma coagulation.
[cited by applicant]
Waibel et al (2011) Safety of chitosan bandages in shellfish allergic patients.
[cited by applicant]
Wei et al. (1999) Electrokinetic properties of colloidal zirconia powders in aqueous suspension.
[cited by applicant]
Wolberg (2007) Thrombin generation and fibrin clot structure.
[cited by applicant]
Xia et al. (2009) Polyethyleneimine Coating Enhances the Cellular Uptake of Mesoporous Silica Nanoparticles and Allows Safe Delivery of siRNA and DNA Constructs.
[cited by applicant]
Xue M, Cao D, Stoddart JF, & Zink JI (2012) Size-selective pH-operated megagates on mesoporous silica materials.
[cited by applicant]
Zreiqat et al. (2002) Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants.
[cited by applicant]
Gegel et al. (2012) The effects of QuikClot Combat Gauze and movement on hemorrhage control in a porcine model. Military Medicine 177(12):1543-1547.
[cited by applicant]